Aceglutamide

Last updated
Aceglutamide
Aceglutamide.svg
Names
Preferred IUPAC name
2-Acetamido-5-amino-5-oxopentanoic acid
Other names
2-(Acetylamino)-glutaramidic acid
α-N-Acetylglutamine; [1]
N-Acetylglutamine
N-Acetyl-L-glutamine
Identifiers
3D model (JSmol)
ChemSpider
DrugBank
ECHA InfoCard 100.017.862 OOjs UI icon edit-ltr-progressive.svg
EC Number
  • 219-647-7
KEGG
MeSH aceglutamide
PubChem CID
UNII
  • InChI=1S/C7H12N2O4/c1-4(10)9-5(7(12)13)2-3-6(8)11/h5H,2-3H2,1H3,(H2,8,11)(H,9,10)(H,12,13) Yes check.svgY
    Key: KSMRODHGGIIXDV-UHFFFAOYSA-N Yes check.svgY
  • CC(=O)NC(CCC(N)=O)C(O)=O
Properties
C7H12N2O4
Molar mass 188.183 g·mol−1
AppearanceWhite crystals
Melting point 197 °C (387 °F; 470 K)
Related compounds
Related alkanoic acids
Related compounds
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Aceglutamide (brand name Neuramina), or aceglutamide aluminium (brand name Glumal), also known as acetylglutamine, is a psychostimulant, nootropic, and antiulcer agent that is marketed in Spain and Japan. [1] [2] [3] [4] It is an acetylated form of the amino acid L-glutamine, the precursor of glutamate in the body and brain. [5] Aceglutamide functions as a prodrug to glutamine with improved potency and stability. [5]

Aceglutamide is used as a psychostimulant and nootropic, while aceglutamide aluminium is used in the treatment of ulcers. [6] [7] [8] [9] Aceglutamide can also be used as a liquid-stable source of glutamine to prevent damage from protein energy malnutrition. [10] [11] [12] The drug has shown neuroprotective effects in an animal model of cerebral ischemia. [5]

See also

Related Research Articles

<span class="mw-page-title-main">Phenylpiracetam</span> Chemical compound

Phenylpiracetam, is a phenylated analog of the drug piracetam. It was developed in 1983 as a medication for Soviet Cosmonauts to treat the prolonged stresses of working in space. Phenylpiracetam was created at the Russian Academy of Sciences Institute of Biomedical Problems in an effort led by psychopharmacologist Valentina Ivanovna Akhapkina. In Russia it is now available as a prescription drug. Research on animals has indicated that phenylpiracetam may have anti-amnesic, antidepressant, anticonvulsant, anxiolytic, and memory enhancement effects.

<span class="mw-page-title-main">Enprostil</span> Chemical compound

Enprostil is a synthetic prostaglandin designed to resemble dinoprostone. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion. It is an analog of prostaglandin E2 but unlike this prostaglandin, which binds to and activates all four cellular receptors viz., EP1, EP2, EP3, and EP4 receptors, enprostil is a more selective receptor agonist in that it binds to and activates primarily the EP3 receptor. Consequently, enprostil is expected to have a narrower range of actions that may avoid some of the unwanted side-effects and toxicities of prostaglandin E2. A prospective multicenter randomized controlled trial conducted in Japan found combining enprostil with cimetidine was more effective than cimetidine alone in treating gastric ulcer.

<span class="mw-page-title-main">NMDA receptor antagonist</span> Class of anesthetics

NMDA receptor antagonists are a class of drugs that work to antagonize, or inhibit the action of, the N-Methyl-D-aspartate receptor (NMDAR). They are commonly used as anesthetics for human and non-human animals; the state of anesthesia they induce is referred to as dissociative anesthesia.

<span class="mw-page-title-main">Citicoline</span> Chemical compound

Citicoline (INN), also known as cytidine diphosphate-choline (CDP-Choline) or cytidine 5'-diphosphocholine is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue, in particular the organs.

<span class="mw-page-title-main">Nizofenone</span> Chemical compound

Nizofenone is a neuroprotective drug which protects neurons from death following cerebral anoxia. It might thus be useful in the treatment of acute neurological conditions such as stroke.

<span class="mw-page-title-main">Ibudilast</span> Chemical compound

Ibudilast is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes.

<span class="mw-page-title-main">SCH-58261</span> Chemical compound

SCH-58261 is a drug which acts as a potent and selective antagonist for the adenosine receptor A2A, with more than 50x selectivity for A2A over other adenosine receptors. It has been used to investigate the mechanism of action of caffeine, which is a mixed A1 / A2A antagonist, and has shown that the A2A receptor is primarily responsible for the stimulant and ergogenic effects of caffeine, but blockade of both A1 and A2A receptors is required to accurately replicate caffeine's effects in animals. SCH-58261 has also shown antidepressant, nootropic and neuroprotective effects in a variety of animal models, and has been investigated as a possible treatment for Parkinson's disease.

<span class="mw-page-title-main">Benexate</span> Chemical compound

Benexate (BEX) is an anti-ulcer agent used in the treatment of acid-related disorders. It is unique in its inability to form salts that are both non-bitter and soluble.

<span class="mw-page-title-main">Aptiganel</span> Chemical compound

Aptiganel is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke. It has neuroprotective effects and was researched for potential use in the treatment of stroke, but despite positive results in animal studies, human trials showed limited efficacy, as well as undesirable side effects such as sedation and hallucinations, and clinical development was ultimately not continued.

<span class="mw-page-title-main">Troxipide</span> Chemical compound

Troxipide is a drug used in the treatment of gastroesophageal reflux disease. Troxipide is a systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum. Troxipide is currently marketed in Japan (Aplace), China (Shuqi), South Korea (Defensa), and India (Troxip). It is used for the management of gastric ulcers, and amelioration of gastric mucosal lesions in acute gastritis and acute exacerbation of chronic gastritis.

<span class="mw-page-title-main">Leteprinim</span> Chemical compound

Leteprinim is a hypoxanthine derivative drug with neuroprotective and nootropic effects. It stimulates release of nerve growth factors and enhances survival of neurons in the brain, and is under development as a potential treatment for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and stroke.

<span class="mw-page-title-main">Bifemelane</span> Antidepressant and cerebral activator drug

Bifemelane (INN) (Alnert, Celeport), or bifemelane hydrochloride (JAN), also known as 4-(O-benzylphenoxy)-N-methylbutylamine, is an antidepressant and cerebral activator that is widely used in the treatment of cerebral infarction patients with depressive symptoms in Japan, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma. Bifemelane acts as a monoamine oxidase inhibitor (MAOI) of both isoenzymes, with competitive (reversible) inhibition of MAO-A (Ki = 4.20 μM) (making it a reversible inhibitor of monoamine oxidase A (RIMA)) and non-competitive (irreversible) inhibition of MAO-B (Ki = 46.0 μM), and also acts (weakly) as a norepinephrine reuptake inhibitor. The drug has nootropic, neuroprotective, and antidepressant-like effects in animal models, and appears to enhance the cholinergic system in the brain.

<span class="mw-page-title-main">Indeloxazine</span> Antidepressant and cerebral activator

Indeloxazine (INN) is an antidepressant and cerebral activator that was marketed in Japan and South Korea by Yamanouchi Pharmaceutical Co., Ltd for the treatment of psychiatric symptoms associated with cerebrovascular diseases, namely depression resulting from stroke, emotional disturbance, and avolition. It was marketed from 1988 to 1998, when it was removed from the market reportedly for lack of effectiveness.

<span class="mw-page-title-main">Amfonelic acid</span> Chemical compound

Amfonelic acid is a research chemical and dopaminergic stimulant with antibiotic properties. Although limited clinical trials have been conducted, it's primarily used in scientific research.

<span class="mw-page-title-main">BRL-52537</span> Chemical compound

BRL-52537 is a drug which acts as a potent and highly selective κ-opioid agonist. It has neuroprotective effects in animal studies, and is used for research into potential treatments for stroke and heart attack as well as more general brain research.

<span class="mw-page-title-main">Teniloxazine</span> Chemical compound

Teniloxazine, also known as sufoxazine and sulfoxazine, is a drug which is marketed in Japan. Though initially investigated as a neuroprotective and nootropic agent for the treatment of cerebrovascular insufficiency in the 1980s, it was ultimately developed and approved as an antidepressant instead. It acts as a potent norepinephrine reuptake inhibitor, with fair selectivity over the serotonin and dopamine transporters, and also behaves as an antagonist of the 5-HT2A receptor.

<span class="mw-page-title-main">Lomerizine</span> Chemical compound

Lomerizine (INN) is a diphenylpiperazine class L-type and T-type calcium channel blocker. This drug is currently used clinically for the treatment of migraines, while also being used experimentally for the treatment of glaucoma and optic nerve injury.

<span class="mw-page-title-main">Licostinel</span> Chemical compound

Licostinel (INN) is a competitive, silent antagonist of the glycine site of the NMDA receptor. It was under investigation by Acea Pharmaceuticals as a neuroprotective agent for the treatment of cerebral ischemia associated with stroke and head injuries but was ultimately never marketed. In clinical trials, licostinel did not produce phencyclidine-like psychotomimetic effects at the doses tested, though transient sedation, dizziness, and nausea were observed. In addition to its actions at the NMDA receptor, licostinel also acts as an antagonist of the AMPA and kainate receptors at high concentrations.

<span class="mw-page-title-main">Acid peptic diseases</span> Overview of the acid peptic diseases of the stomach and gastrointestinal tract

Acid peptic diseases, such as peptic ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease, are caused by distinct but overlapping pathogenic mechanisms involving acid effects on mucosal defense. Acid reflux damages the esophageal mucosa and may also cause laryngeal tissue injury, leading to the development of pulmonary symptoms.

A cerebroprotectant is a drug that is intended to protect the brain after the onset of acute ischemic stroke. As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs tested in clinical trials to provide cerebroprotection.

References

  1. 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 3–. ISBN   978-1-4757-2085-3.
  2. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 6–. ISBN   978-3-88763-075-1.
  3. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 35–. ISBN   978-0-8155-1856-3.
  4. ↑ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 3–. ISBN   978-94-011-4439-1.
  5. 1 2 3 Zhang R, Yang N, Ji C, Zheng J, Liang Z, Hou CY, et al. (2015). "Neuroprotective effects of Aceglutamide on motor function in a rat model of cerebral ischemia and reperfusion". Restorative Neurology and Neuroscience. 33 (5): 741–59. doi:10.3233/RNN-150509. PMID   26444640.
  6. ↑ Ito M, Yokochi E, Kobayashi C, Suzuki Y (April 1982). "[Studies on defensive factors of experimental ulcers (2). Increasing action of aceglutamide aluminium on defensive factors in acetic acid ulcers of rats (author's transl)]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 79 (4): 327–34. doi: 10.1254/fpj.79.327 . PMID   7095654.
  7. ↑ Harada M, Yano S (1974). "Inhibitory effect of N-acetyl-L-glutamine aluminium complex (KW-110) and related compounds on gastric erosion and motility in stressed animals". Oyo Yakuri. 8 (1): 1–6.
  8. ↑ Varas Lorenzo MJ, López Martínez A, Gordillo Bernal J, Mundet Surroca J (August 1991). "[Comparative study of 3 drugs (aceglutamide aluminium, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]". Revista Espanola de Enfermedades Digestivas. 80 (2): 91–4. PMID   1790087.
  9. ↑ Tanaka H, Shuto K, Marumo H (April 1982). "Effect of N-acetyl-L-glutamine aluminium complex (KW-110), an antiulcer agent, on the non-steroidal anti-inflammatory drug-induced exacerbation of gastric ulcer in rats". Japanese Journal of Pharmacology. 32 (2): 307–13. doi: 10.1254/jjp.32.307 . PMID   7098147.
  10. ↑ López-Pedrosa JM, Manzano M, Baxter JH, Rueda R (March 2007). "N-acetyl-L-glutamine, a liquid-stable source of glutamine, partially prevents changes in body weight and on intestinal immunity induced by protein energy malnutrition in pigs". Digestive Diseases and Sciences. 52 (3): 650–8. doi:10.1007/s10620-006-9500-y. PMID   17253138. S2CID   37484555.
  11. ↑ JP H10101576,Sasaki, Kazuyuki&Hayakawa, Toru,"Treating medicine for digestive organ disease",published 1998-04-21, assigned to Nisshin Flour Milling Co Ltd.
  12. ↑ USapplication 2003099722,Baxter, Jeffrey,"Methods and compositions for providing glutamine",published 2003-05-29, assigned to Abbott Laboratories , abandoned during patent examination
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.